Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study

References

• Tada Y, Ishii K, Kimura J, et al. Patient preference for biologic treatments of psoriasis in Japan. J Dermatol. 2019;46(6):1–11. doi: 10.1111/1346-8138.14870.
   Web of Science ®Google Scholar
• Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the japanese national claims database. BMJ Open. 2015;5(1):e006450. doi: 10.1136/bmjopen-2014-006450.
   PubMed Web of Science ®Google Scholar
• Kamiya K, Oiso N, Kawada A, et al. Epidemiological survey of the psoriasis patients in the japanese society for psoriasis research from 2013 to 2018. J Dermatol. 2021;48(6):864–875. doi: 10.1111/1346-8138.15803.
   PubMed Web of Science ®Google Scholar
• Ogawa E, Okuyama R, Seki T, et al. Epidemiological survey of patients with psoriasis in matsumoto city, Nagano prefecture, Japan. J Dermatol. 2018;45(3):314–317. doi: 10.1111/1346-8138.14101.
   PubMed Web of Science ®Google Scholar
• Feldman SR. Treatment of psoriasis in adults: upToDate; 2022 updated 2022 Oct 12; [cited 2022 Nov 02]. Available from: https://www.uptodate.com/contents/treatment-of-psoriasis-in-adults#H45.
   Google Scholar
• List of Approved Products: Pharmaceuticals and Medical Devices Agency; [cited 2022 Nov 02]. Available from: https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html.
   Google Scholar
• BIMZELX[®] (bimekizumab) Approved in Japan for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Psoriatic Erythroderma: UCB. 2022; [cited 2022 Nov 28]. Available from: https://www.ucb.com/stories-media/Press-Releases/article/BIMZELXR-bimekizumab-Approved-in-Japan-for-the-Treatment-of-Plaque-Psoriasis-Generalized-Pustular-Psoriasis-and-Psoriatic-Erythroderma#:∼:text=Bimekizumab%20is%20the%20first%20approved,17A%20(IL%2D17A).
   Google Scholar
• Nippon Boehringer Ingelheim Receives Manufacturing and Marketing Approval for “Spevigo® Intravenous Infusion 450mg” for Treatment of Acute Pustular Psoriasis: Boehringer Ingelheim; [updated September 26, 2022; March 13, 2023]. Available from: https://www.boehringer-ingelheim.jp/press-release/20220926_01.
   Google Scholar
• New Drugs Approved in FY. 2016: Pharmaceuticals and Medical Devices Agency; [cited 2022 Nov 02]. Available from: https://www.pmda.go.jp/files/000232770.pdf.
   Google Scholar
• New Drugs Approved in FY. 2021: Pharmaceuticals and Medical Devices Agency; [cited 2022 Nov 02]. Available from: https://www.pmda.go.jp/files/000246734.pdf.
   Google Scholar
• Tada Y, Kim H, Spanopoulos D, et al. Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: a retrospective claims database study. J Dermatol. 2022;49(11):1106–1117. doi: 10.1111/1346-8138.16543.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Zhu B, Malatestinic WN, et al. Real-world biologic adherence, persistence, and monotherapy comparisons in US patients with psoriasis: results from IBM MarketScan((R)) databases. Adv Ther. 2022;39(7):3214–3224. doi: 10.1007/s12325-022-02155-9.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Shi N, Burge R, et al. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab. J Am Acad Dermatol. 2020;82(4):927–935. doi: 10.1016/j.jaad.2019.11.015.
   PubMed Web of Science ®Google Scholar
• Lockshin B, Cronin A, Harrison RW, et al. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the Corrona psoriasis registry. Dermatol Ther. 2021;34(2):e14808.
   PubMed Web of Science ®Google Scholar
• Kishimoto M, Komine M, Kamiya K, et al. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. J Dermatol. 2020;47(1):33–40. doi: 10.1111/1346-8138.15146.
   PubMed Web of Science ®Google Scholar
• Bayaraa B, Imafuku S. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka university psoriasis registry. J Dermatol. 2019;46(5):389–398. doi: 10.1111/1346-8138.14834.
   PubMed Web of Science ®Google Scholar
• Sruamsiri R, Iwasaki K, Tang W, et al. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database. BMC Dermatol. 2018;18(1):5. doi: 10.1186/s12895-018-0074-0.
   PubMedGoogle Scholar
• Ohata C, Ohyama B, Katayama E, et al. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: a single-center experience. J Dermatol. 2020;47(4):405–408. doi: 10.1111/1346-8138.15247.
   PubMed Web of Science ®Google Scholar
• Matsuda S. Development of case mix based evaluation system in Japan. Jpn Hosp. 2016;(35):35–44.
   PubMedGoogle Scholar
• Hayashida K, Murakami G, Matsuda S, et al. History and profile of diagnosis procedure combination (DPC): development of a real data collection system for acute inpatient care in Japan. J Epidemiol. 2021;31(1):1–11. doi: 10.2188/jea.JE20200288.
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139. doi: 10.1097/01.mlr.0000182534.19832.83.
   PubMed Web of Science ®Google Scholar
• Jungo P, Maul JT, Djamei V, et al. Superiority in quality of life improvement of biologics over conventional systemic drugs in a swiss Real-Life psoriasis registry. Dermatology. 2016;232(6):655–663. doi: 10.1159/000455042.
   PubMed Web of Science ®Google Scholar
• Colombo D, Bianchi L, Fabbrocini G, et al. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study. Dermatol Ther. 2022;35(1):e15166.
   PubMed Web of Science ®Google Scholar
• Xu C, Teeple A, Wu B, et al. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population. J Dermatolog Treat. 2022;33(4):2270–2277. doi: 10.1080/09546634.2021.1950600.
   PubMed Web of Science ®Google Scholar
• Pina Vegas L, Penso L, Claudepierre P, et al. Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the french health insurance database. JAMA Dermatol. 2022;158(5):513–522. doi: 10.1001/jamadermatol.2022.0364.
   PubMed Web of Science ®Google Scholar
• Perrone V, Losi S, Filippi E, et al. Analysis of the pharmacoutilization of biological drugs in psoriatic arthritis patients: a real-world retrospective study among an Italian population. Rheumatol Ther. 2022;9(3):875–890. doi: 10.1007/s40744-022-00440-1.
   PubMed Web of Science ®Google Scholar
• Walsh JA, Cai Q, Lin I, et al. Treatment persistence and adherence among patients with psoriatic arthritis who initiated targeted immune modulators in the US: a retrospective cohort study. Adv Ther. 2021;38(5):2353–2364. doi: 10.1007/s12325-021-01687-w.
   PubMed Web of Science ®Google Scholar
• Kojanova M, Hugo J, Velackova B, et al. Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry. J Dermatolog Treat. 2022;33(6):2827–2837. doi: 10.1080/09546634.2022.2082354.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Roseno NAL, Aagaard D, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis – a nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53:151979. doi: 10.1016/j.semarthrit.2022.151979.
   PubMed Web of Science ®Google Scholar
• Pizzicato LN, Vadhariya A, Birt J, et al. Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States. J Manag Care Spec Pharm. 2023;29(1):24–35.
   PubMed Web of Science ®Google Scholar
• Torres T, Puig L, Vender R, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective Multi-Country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567–579. doi: 10.1007/s40257-021-00598-4.
   PubMed Web of Science ®Google Scholar
• Wade R, Sharif-Hurst S, Dias S. Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups. Syst Rev. 2020;9(1):132. doi: 10.1186/s13643-020-01395-6.
   PubMed Web of Science ®Google Scholar
• Yiu ZZN, Becher G, Kirby B, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158(10):1131–1141. doi: 10.1001/jamadermatol.2022.2909.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Burge R, Gallo G, et al. A retrospective cohort analysis of treatment patterns over 1 year in patients with psoriasis treated with ixekizumab or guselkumab. Dermatol Ther . 2022;12(3):701–714. doi: 10.1007/s13555-022-00686-1.
   Web of Science ®Google Scholar
• Xu C, Teeple A, Wu B, et al. Drug adherence and persistence of patients with moderate to severe psoriasis treated with biologic medications in a US commercially insured population. Dermatology. 2022;238(3):438–447. doi: 10.1159/000519176.
   PubMed Web of Science ®Google Scholar
• Wang CY, Foley P, Baker C, et al. Biological therapy interruption and Re-treatment in chronic plaque psoriasis. J Drugs Dermatol. 2021;20(10):1063–1071.
   PubMed Web of Science ®Google Scholar
• Saeki H, Mabuchi T, Asahina A, et. al. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). J Dermatol. 2023;50(2):e41–e68. doi: 10.1111/1346-8138.16691.
   Google Scholar
• Uchida H, Kamata M, Egawa S, et al. Impact of the COVID-19 pandemic on biologic treatment in psoriasis patients: a single-center retrospective study in Japan. J Dermatol. 2022;49(6):624–628. doi: 10.1111/1346-8138.16362.
   PubMed Web of Science ®Google Scholar